Therapeutic effect of bone marrow stromal cells and coenzyme Q10 on rat models of parkinson's disease

ABSTRACT

The assessment of the ability of combined treatment of bone marrow stromal cells graft [BMSCs] and oral administration of Coenzyme [CoQIO] in rat model of Parkinson disease as a good substitute for common current Parkinson treatments, and the comparison of this combined treatment method with alone application of these treatments. In this experimental study of male Wistar rats were used. They were divided into six groups control, sham, lesion, treatment groups with oral administration of CoQIO, treatment with graft BMSC and combined treatment with graft BMSC and oral administration of CoQIO. Oral administration of CoQIO with 200 mg/kg/daily dose started a week before the model creation procedure and continued throughout the whole treatment period. The laboratory model of Parkinson disease in rats was performed by injecting 2.5 microlitre saline solution 0.9% containing 8 micrograms 6-hydroxy dopamine [6-OHDA] and 0.2% ascorbic acid in substantia nigra pars compacta. Also in sham group the same volume solution saline-ascorbic was injected. BMS Cells were labeled by 5-Bromo-2'-deoxyuridine [Brdu] before transplantation. Behavioral assessment before creating the model, two weeks after creating the model and eight weeks after cell transplantation was performed. At the end of second month of treatment, Immunohistochemistry and histology Studies were performed. Behavioral assessment of two groups of alone treatments indicated the equal recovery in comparison with lesion group [p<0.01] while combined treatment of BMSC and Co Q10 showed a considerable recovery compared with lesion group [p<0.001]. In addition according to histological studies, no sign of gliosis and graft rejection was seen. Immunohistochemistry studies of Brdu indicate that the cells are alive after two month of application in host tissue. Cell count assessment showed that the number of neural cells in combined treatment of BMSC and Co Q10 was significant difference with others experimental groups [p<0.001]. The combined use of two neuroprotective treatment and replacement therapy can have a more effective role in the treatment of Parkinson's disease in comparison of alone treatment protocols